Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer

References

• Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:117–12. doi:10.1161/01.CIR.0000078466.72504.AC.
   Web of Science ®Google Scholar
• Gran OV, Smith EN, Braekkan SK, Jensvoll H, Solomon T, Hindberg K, Wilsgaard T, Rosendaal FR, Frazer KA, Hansen JB. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica. 2016;101:1046–1053. doi:10.3324/haematol.2016.147405.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11:223–233. doi:10.1111/jth.12075.
   PubMed Web of Science ®Google Scholar
• Dahlback B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol. 2016;38(Suppl 1):4–11. doi:10.1111/ijlh.12508.
   PubMedGoogle Scholar
• Liang HP, Kerschen EJ, Basu S, Hernandez I, Zogg M, Jia S. Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood. 2015;126:2415–2423. doi:10.1182/blood-2015-05-644401.
   PubMed Web of Science ®Google Scholar
• Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer. 2014;14:845. doi:10.1186/1471-2407-14-845.
   PubMed Web of Science ®Google Scholar
• Tinholt M, Garred O, Borgen E, Beraki E, Schlichting E, Kristensen V. Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study. J Thromb Haemost. 2018;16:1347–1356. doi:10.1111/jth.14151.
   PubMed Web of Science ®Google Scholar
• Aure MR, Vitelli V, Jernstrom S, Kumar S, Krohn M, Due EU. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Res. 2017;19:44. doi:10.1186/s13058-017-0812-y.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. [accessed 2017 Aug 15]. https://cancergenome.nih.gov/.
   Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al.. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. doi:10.1126/scisignal.2004088.
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13. doi:10.1093/nar/gkn923.
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. doi:10.1038/nprot.2008.211.
   PubMed Web of Science ®Google Scholar
• Supek F, Bosnjak M, Skunca N, Smuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011;6:e21800. doi:10.1371/journal.pone.0021800.
   PubMed Web of Science ®Google Scholar
• Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One. 2011;6:e17911. doi:10.1371/journal.pone.0017911.
   PubMed Web of Science ®Google Scholar
• Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A. 2008;105:14094–14099. doi:10.1073/pnas.0804455105.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–731.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e10. doi:10.1158/0008-5472.CAN-17-0307.
   PubMed Web of Science ®Google Scholar
• Gil M, Kim KE. Interleukin-18 is a prognostic biomarker correlated with CD8(+) T cell and natural killer cell infiltration in skin cutaneous melanoma. J Clin Med. 2019;8:1993.
   PubMed Web of Science ®Google Scholar
• Ruan M, Tian T, Rao J, Xu X, Yu B, Yang W, et al.. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. Diagn Pathol. 2018;13:66. doi:10.1186/s13000-018-0743-7.
   PubMed Web of Science ®Google Scholar
• Tian T, Ruan M, Yang W, Shui R. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. Oncotarget. 2016;7:44395–44405. doi:10.18632/oncotarget.10054.
   PubMedGoogle Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• The database for annotation, visualization and integrated discovery (DAVID). [accessed 2017 Sep 20. https://david.ncifcrf.gov/.
   Google Scholar
• Fredlund E, Staaf J, Rantala JK, Kallioniemi O, Borg A, Ringner M. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res. 2012;14:R113. doi:10.1186/bcr3236.
   PubMed Web of Science ®Google Scholar
• Degen JL, Palumbo JS. Hemostatic factors, innate immunity and malignancy. Thromb Res. 2012;129(Suppl 1):S1–5. doi:10.1016/S0049-3848(12)70143-3.
   PubMedGoogle Scholar
• Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007;8:R157. doi:10.1186/gb-2007-8-8-r157.
   PubMed Web of Science ®Google Scholar
• Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, et al. Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 2010;28(11):1813–1820. doi:10.1200/JCO.2009.22.8775.
   PubMed Web of Science ®Google Scholar
• Zhang SC, Hu ZQ, Long JH, Zhu GM, Wang Y, Jia Y, et al. Clinical implications of tumor-infiltrating immune cells in breast cancer. J Cancer. 2019;10:6175–6184. doi:10.7150/jca.35901.
   PubMed Web of Science ®Google Scholar
• Tekpli X, Lien T, Rossevold AH, Nebdal D, Borgen E, Ohnstad HO, et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019;10:5499. doi:10.1038/s41467-019-13329-5.
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267–1284. doi:10.1101/gad.314617.118.
   PubMed Web of Science ®Google Scholar
• Morrow ES, Roseweir A, Edwards J. The role of gamma delta T lymphocytes in breast cancer: a review. Transl Res. 2019; 203:88–96. doi:10.1016/j.trsl.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174. doi:10.1016/j.redox.2019.101174.
   PubMed Web of Science ®Google Scholar
• Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sonderby CK, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 2016;44:D917–24. doi:10.1093/nar/gkv1101.
   PubMed Web of Science ®Google Scholar
• Nirmal AJ, Regan T, Shih BB, Hume DA, Sims AH, Freeman TC. Immune cell gene signatures for profiling the microenvironment of solid tumors. Cancer Immunol Res. 2018;6:1388–1400. doi:10.1158/2326-6066.CIR-18-0342.
   PubMed Web of Science ®Google Scholar
• Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2:549–557. doi:10.1002/rth2.12109.
   PubMed Web of Science ®Google Scholar
• Rallabhandi P, Nhu QM, Toshchakov VY, Piao W, Medvedev AE, Hollenberg MD, et al. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J Biol Chem. 2008;283:24314–24325. doi:10.1074/jbc.M804800200.
   PubMed Web of Science ®Google Scholar
• Ubil E, Caskey L, Holtzhausen A, Hunter D, Story C, Earp HS. Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest. 2018;128:2356–2369. doi:10.1172/JCI97354.
   PubMed Web of Science ®Google Scholar
• Graf C, Wilgenbus P, Pagel S, Pott J, Marini F, Reyda S, et al. Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci Immunol. 2019;4:eaaw8405.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liao XW, Qin YZ, Mo XW, Luo SS. Identification of F5 as a prognostic biomarker in patients with gastric cancer. Biomed Res Int. 2020. doi:10.1155/2020/9280841.
   Google Scholar
• Astoul E, Edmunds C, Cantrell DA, Ward SG. PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol. 2001;22:490–496. doi:10.1016/S1471-4906(01)01973-1.
   PubMed Web of Science ®Google Scholar